Photo by nci from unsplash
While most patients with mantle cell lymphoma (MCL) receive therapy shortly after diagnosis, a subset of patients with indolent‐behaving disease can safely defer treatment. In this subgroup, we evaluated the… Click to show full abstract
While most patients with mantle cell lymphoma (MCL) receive therapy shortly after diagnosis, a subset of patients with indolent‐behaving disease can safely defer treatment. In this subgroup, we evaluated the importance of treatment intensity in patients with MCL who defer initial therapy.
Keywords:
intensive induction;
mantle cell;
initial therapy;
cell lymphoma
Journal Title: European Journal of Haematology
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: European Journal of Haematology
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!